Quit or Switch: E-cigarette Study

What Was Tested

The trial (not phased) is built around Therapeutic nicotine (patch, non-peptide).

It had two arms (groups): Switch Group (experimental) and Meds Group (active comparator).

Participants in the Switch group will receive a 5-week supply of e-cigarettes.

Participants in the Meds Group will receive a 5-week supply of combination nicotine replacement therapy (transdermal nicotine patch and short-acting nicotine lozenge).

The registry classes the interventions as behavioral and other.

Who Took Part

The registry lists 30 actual participants took part.

It was open to people of any sex aged from 21 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: At least 21 years old. Smoking at least 5 cigarettes per day for 1 year. Intention to quit smoking within the next month. Access to daily e-mail or a smartphone that receives text messages.

The full record lists 5 inclusion and 6 exclusion criteria; among the exclusions: use of non-cigarette tobacco products in the past 30 days; pregnant, breastfeeding, or trying to become pregnant; household member currently enrolled in the study.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2022-08-01 with completion listed for 2023-07-17.

It ran at 1 site in United States.

Its stated primary purpose is prevention.

What Was Measured

Researchers chose this as the main measure: Percentage of Participants Who Report Daily Use of E-cigarettes or NRT and no Cigarette Use (time frame: day 0 through day 35). Percentage of Participants Who Have Biochemically-confirmed Abstinence From Cigarette Smoking at Week 4 (time frame: Week 4).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Therapeutic nicotine (patch, non-peptide) in 30 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.